Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 19CNS 4Endocrine 3Dermatologic 3Other solid neoplasm 2Gynecologic 2Genitourinary 2Gastrointestinal 2Thoracic 1Other hematologic neoplasm 1NET 1Lymphoid 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 296Cytarabine 261fludarabine phosphate 218Rituximab 195fludarabine 182Methotrexate 152Whole-Body Irradiation 140Mycophenolic Acid 124Azacitidine 122Tacrolimus 116Busulfan 110Filgrastim 104Granulocyte Colony-Stimulating Factor 98Etoposide 91Peripheral Blood Stem Cell Transplantation 90Dexamethasone 89Vincristine 88Melphalan 80Cyclosporine 74Lenalidomide 73Daunorubicin 70Decitabine 69Clofarabine 69Antilymphocyte Serum 67Calcium Dobesilate 61venetoclax 60Doxorubicin 58Imatinib Mesylate 57Alemtuzumab 56ibrutinib 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × ribociclib × Other hematologic neoplasm × Clear all
NCT02187783 2019-07-18

SIGNATURE

Novartis

Phase 2 Completed
106 enrolled 16 charts
BreastGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmThoracic

Breast Neoplasms, Leukemia, Lymphoma, Mesothelioma, Neoplasms, Ovarian Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡